Mar 27, 2013 (ACCESSWIRE-TNW via COMTEX) -- NEW YORK, March 27, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Bank of America Corp, Morgan Stanley, Qualcomm.
Gilead Sciences, Inc. (NASDAQ:GILD) stock increased 2.60% to $46.96. The company, on Mar. 26, said the phase 3 trial ION-1, evaluating once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A inhibitor ledipasvir with and without ribavirin for 12 or 24 weeks among treatment-naïve genotype 1 patients with hepatitis C virus infection should continue without any modification.
Additionally, GILD's stock had its "neutral" rating reiterated by Zacks in a note issued to investors on Mar. 26. They currently have a $47.00 target price on the stock.
Is GILD a Strong Buy At New highs? Find Out Here http://bestdarnpennystocks.com/landing/home-aw.php?code=GILD (OR Just copy and paste the link)
Moreover, the company released its earnings data on Feb. 4. The company reported $0.50 earnings per share for the quarter, beating the analysts' consensus estimate of $0.48 by $0.02. The company had revenue of $2.59 billion for the quarter, compared to the consensus estimate of $2.43 billion.
J.C. Penney Company, Inc.(NYSE:JCP) shares declined 1.33% to $14.80. Equities researchers at Piper Jaffray dropped their target price on shares of JCP from $16.00 to $14.00 in a report issued on Mar. 25. The firm
currently has a "neutral" rating on the stock.
Additionally, the company, on Mar. 21, cut 27% of its workforce last year as the retailer struggled to turn itself around. The department store chain slashed 43,000 jobs, according to its annual report filed with the Securities and Exchange Commission. J.C. Penney reported a total of 116,000 full-time and part-time workers at the end of its fiscal year that ended February, down from 159,000 workers last year.
Should Investors Buy JCP After The Recent Slump? Get Free Trend Analysis Here http://bestdarnpennystocks.com/landing/home-aw.php?code=JCP (OR Just copy and paste the link)
Moreover, the company issued its quarterly earnings data on Feb. 27. The company reported ($1.95) EPS for the quarter, missing the consensus estimate of ($0.17) by $1.78. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $4.08 billion.
Meanwhile SK3 Group, Inc.(PINK:SKTO) has appointed Jeffrey Benz, an experienced business attorney and former executive with several sports, entertainment, and technology companies, as General Counsel and Executive Vice President of Business, Legal, and Government Affairs.
Is SKTO a Buy After Today's Correction? Get Free Report http://bestdarnpennystocks.com/landing/home-aw.php?code=SKTO (OR Just copy and paste the link)
Kevin Allyn, Chairman of SK3, said in his statement: Here "We are bringing together a management team with the unique and demonstrated abilities to drive our business to success. Jeff Benz has broad experience as a senior executive, lawyer, and entrepreneur in entertainment, sports, licensing, intellectual property, and technology. Jeff has been a trusted advisor to a variety of companies, both private and public, and has advised a number of high profile executives. Among other things, Mr. Benz was the General Counsel and head of business and government affairs for the United States Olympic Committee, AVP Pro Beach Volleyball Tour, and a variety of private companies in sports, entertainment (television, film, and online), and technology (mobile phone applications, computer software and hardware, and
medical devices), and has lead high profile legal and operational functions in a wide array of industries, including internationally. Mr. Benz's extraordinary experience and background, and his legal leadership skills, uniquely fit our current needs and will lead SKTO into lucrative new markets."
Benz will also assist with activities like recruitment, sourcing, and documenting relationships with key executives and partners. SK3 now focuses purely on the medical marijuana space.
bestdarnpennystocks.com's team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
The assembled information disseminated by bestdarnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. bestdarnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in bestdarnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
1419 Westwood Blvd Los Angeles, CA
Copyright 2013 ACCESSWIRE-TNW